Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The serotonin 5‑HT₂A receptor (5-HT2A) is a G protein-coupled receptor that primarily couples to Gq/11 proteins, leading to activation of intracellular signaling cascades. It is highly expressed in the central nervous system, especially the frontal cortex, and is involved in cognition, memory formation, and mood regulation. Peripherally, it mediates vasoconstriction and platelet aggregation. Psychedelic drugs such as LSD and psilocybin are potent agonists, while many atypical antipsychotics act as antagonists. Overexpression or abnormal activity is linked with depression and schizophrenia. Activation by psychedelics promotes neuroplasticity.
Agonism (e.g., LSD, psilocybin); Antagonism (e.g., atypical antipsychotics); Modulation of dopamine release; Activation of PLC/IP₃/DAG/Ca²⁺ pathway
3 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Serotonin 5‑HT₂A Receptor (5-HT2A).